Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 336

1.

Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion.

Lluch A, González-Angulo AM, Casadevall D, Eterovic AK, Martínez de Dueñas E, Zheng X, Guerrero-Zotano Á, Liu S, Pérez R, Chen K, Chacón JI, Mills GB, Antolín S, Blancas I, López-Serra P, Carrasco E, Caballero R, Prat A, Rojo F, Gonzalez-Perez A, Meric-Bernstam F, Albanell J.

Eur J Cancer. 2019 Sep 3;120:54-64. doi: 10.1016/j.ejca.2019.07.003. [Epub ahead of print]

PMID:
31491604
2.

The contribution of milks and formulae to micronutrient intake in 1-3 years old children in urban China: a simulation study.

Li T, You J, Pean J, Lluch A, Eussen S, Delaere F, Bindels JG, Dai Y.

Asia Pac J Clin Nutr. 2019;28(3):558-566. doi: 10.6133/apjcn.201909_28(3).0015.

3.

Detection of TP53 and PIK3CA Mutations in Circulating Tumor DNA Using Next-Generation Sequencing in the Screening Process for Early Breast Cancer Diagnosis.

Rodriguez BJ, Córdoba GD, Aranda AG, Álvarez M, Vicioso L, Pérez CL, Hernando C, Bermejo B, Parreño AJ, Lluch A, Ryder MB, Jones FS, Fredebohm J, Holtrup F, Queipo-Ortuño MI, Alba E.

J Clin Med. 2019 Aug 7;8(8). pii: E1183. doi: 10.3390/jcm8081183.

4.

Detection of breast cancer stem cell gene mutations in circulating free DNA during the evolution of metastases.

Liu ZB, Ezzedine NE, Eterovic AK, Ensor JE, Huang HJ, Albanell J, Choi DS, Lluch A, Liu Y, Rojo F, Wong H, Martínez-Dueñas E, Guerrero-Zotano Á, Shao ZM, Darcourt JG, Mills GB, Dave B, Chang JC.

Breast Cancer Res Treat. 2019 Aug 6. doi: 10.1007/s10549-019-05374-x. [Epub ahead of print]

PMID:
31388936
5.

Contribution of trastuzumab to the prognostic improvement of HER2-positive early breast cancer in Spain: an estimation of life years and disease-free life years gained since its approval.

Ciruelos E, Alba E, López R, Lluch A, Martín M, Arroyo I, Navarro B, Carcedo D, Colomer R, Albanell J.

Oncotarget. 2019 Jul 2;10(42):4321-4332. doi: 10.18632/oncotarget.27039. eCollection 2019 Jul 2.

6.

High Numbers of Circulating CD57+ NK Cells Associate with Resistance to HER2-Specific Therapeutic Antibodies in HER2+ Primary Breast Cancer.

Muntasell A, Servitja S, Cabo M, Bermejo B, Pérez-Buira S, Rojo F, Costa-García M, Arpí O, Moraru M, Serrano L, Tusquets I, Martínez MT, Heredia G, Vera A, Martínez-García M, Soria L, Comerma L, Santana-Hernández S, Eroles P, Rovira A, Vilches C, Lluch A, Albanell J, López-Botet M.

Cancer Immunol Res. 2019 Aug;7(8):1280-1292. doi: 10.1158/2326-6066.CIR-18-0896. Epub 2019 Jun 12.

PMID:
31189644
7.

Hydrogen sulfide impacts on inflammation-induced adipocyte dysfunction.

Comas F, Latorre J, Cussó O, Ortega F, Lluch A, Sabater M, Castells-Nobau A, Ricart W, Ribas X, Costas M, Fernández-Real JM, Moreno-Navarrete JM.

Food Chem Toxicol. 2019 Sep;131:110543. doi: 10.1016/j.fct.2019.05.051. Epub 2019 May 30.

PMID:
31154084
8.

Cytoskeletal transgelin 2 contributes to gender-dependent adipose tissue expandability and immune function.

Ortega FJ, Moreno-Navarrete JM, Mercader JM, Gómez-Serrano M, García-Santos E, Latorre J, Lluch A, Sabater M, Caballano-Infantes E, Guzmán R, Macías-González M, Buxo M, Gironés J, Vilallonga R, Naon D, Botas P, Delgado E, Corella D, Burcelin R, Frühbeck G, Ricart W, Simó R, Castrillon-Rodríguez I, Tinahones FJ, Bosch F, Vidal-Puig A, Malagón MM, Peral B, Zorzano A, Fernández-Real JM.

FASEB J. 2019 Aug;33(8):9656-9671. doi: 10.1096/fj.201900479R. Epub 2019 May 30.

PMID:
31145872
9.

A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer.

Pascual T, Martin M, Fernández-Martínez A, Paré L, Alba E, Rodríguez-Lescure Á, Perrone G, Cortés J, Morales S, Lluch A, Urruticoechea A, González-Farré B, Galván P, Jares P, Rodriguez A, Chic N, Righi D, Cejalvo JM, Tonini G, Adamo B, Vidal M, Villagrasa P, Muñoz M, Prat A.

Front Oncol. 2019 Apr 26;9:303. doi: 10.3389/fonc.2019.00303. eCollection 2019.

10.

Broad consensus on the optimal sequence for the systemic treatment of metastatic breast cancer: results from a survey of Spanish medical oncologists.

Sánchez-Rovira P, Zamora P, Salvador-Bofill J, Morales S, Martínez-Jáñez N, Martínez-de-Dueñas E, Lluch A, Illarramendi JJ, Gómez-Pardo P, Gavilá Gregori J, García-Palomo A, García-Mata J, Fernández Y, Del Barco S, de Juan A, Ciruelos E, Chacón JI, Calvo L, Barnadas A, Albanell J.

J Drug Assess. 2019 Apr 8;8(1):62-69. doi: 10.1080/21556660.2019.1604375. eCollection 2019.

11.

Comparative and functional analysis of plasma membrane-derived extracellular vesicles from obese vs. nonobese women.

Santamaria-Martos F, Benitez ID, Latorre J, Lluch A, Moreno-Navarrete JM, Sabater M, Ricart W, Sanchez de la Torre M, Mora S, Fernández-Real JM, Ortega FJ.

Clin Nutr. 2019 Apr 17. pii: S0261-5614(19)30163-3. doi: 10.1016/j.clnu.2019.04.008. [Epub ahead of print]

PMID:
31036413
12.

Rationale and Study Design for an Individualized Perioperative Open Lung Ventilatory Strategy in Patients on One-Lung Ventilation (iPROVE-OLV).

Carramiñana A, Ferrando C, Unzueta MC, Navarro R, Suárez-Sipmann F, Tusman G, Garutti I, Soro M, Pozo N, Librero J, Gallego L, Ramasco F, Rabanal JM, Rodriguez A, Sastre J, Martinez J, Coves S, García P, Aguirre-Puig P, Yepes J, Lluch A, López-Herrera D, Leal S, Vives M, Bellas S, Socorro T, Trespalacios R, Salazar CJ, Mugarra A, Cinnella G, Spadaro S, Futier E, Ferrer L, Cabrera M, Ribeiro H, Celestino C, Kucur E, Cervantes O, Morocho D, Delphy D, Ramos C, Villar J, Belda J; iPROVE-OLV Network.

J Cardiothorac Vasc Anesth. 2019 Sep;33(9):2492-2502. doi: 10.1053/j.jvca.2019.01.056. Epub 2019 Feb 8.

PMID:
30928294
13.

The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors.

Tormo E, Ballester S, Adam-Artigues A, Burgués O, Alonso E, Bermejo B, Menéndez S, Zazo S, Madoz-Gúrpide J, Rovira A, Albanell J, Rojo F, Lluch A, Eroles P.

Sci Rep. 2019 Mar 29;9(1):5316. doi: 10.1038/s41598-019-41472-y.

14.

Overeating, caloric restriction and breast cancer risk by pathologic subtype: the EPIGEICAM study.

Lope V, Martín M, Castelló A, Ruiz A, Casas AM, Baena-Cañada JM, Antolín S, Ramos-Vázquez M, García-Sáenz JÁ, Muñoz M, Lluch A, de Juan-Ferré A, Jara C, Sánchez-Rovira P, Antón A, Chacón JI, Arcusa A, Jimeno MA, Bezares S, Vioque J, Carrasco E, Pérez-Gómez B, Pollán M.

Sci Rep. 2019 Mar 7;9(1):3904. doi: 10.1038/s41598-019-39346-4.

15.

Breast Cancer in Very Young Patients in a Spanish Cohort: Age as an Independent Bad Prognostic Indicator.

Martínez MT, Oltra SS, Peña-Chilet M, Alonso E, Hernando C, Burgues O, Chirivella I, Bermejo B, Lluch A, Ribas G.

Breast Cancer (Auckl). 2019 Feb 20;13:1178223419828766. doi: 10.1177/1178223419828766. eCollection 2019.

16.

A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients.

Pineda B, Diaz-Lagares A, Pérez-Fidalgo JA, Burgués O, González-Barrallo I, Crujeiras AB, Sandoval J, Esteller M, Lluch A, Eroles P.

Clin Epigenetics. 2019 Feb 20;11(1):33. doi: 10.1186/s13148-019-0626-0.

17.

Correction: ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors.

Guerrero-Zotano AL, Stricker TP, Formisano L, Hutchinson KE, Stover DG, Lee KM, Schwarz LJ, Giltnane JM, Estrada MV, Jansen VM, Servetto A, Gavilá J, Perez-Fidalgo JA, Lluch A, Llombart-Cussac A, Bayar MA, Michiels S, André F, Arnedos M, Guillem V, Ruiz-Simon A, Arteaga CL.

Clin Cancer Res. 2019 Feb 15;25(4):1431. doi: 10.1158/1078-0432.CCR-18-4270. No abstract available.

18.

Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement.

Colomer R, Saura C, Sánchez-Rovira P, Pascual T, Rubio IT, Burgués O, Marcos L, Rodríguez CA, Martín M, Lluch A.

Oncologist. 2019 May;24(5):603-611. doi: 10.1634/theoncologist.2018-0228. Epub 2019 Feb 1.

PMID:
30710068
19.

NK Cell Infiltrates and HLA Class I Expression in Primary HER2+ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival.

Muntasell A, Rojo F, Servitja S, Rubio-Perez C, Cabo M, Tamborero D, Costa-García M, Martínez-Garcia M, Menéndez S, Vazquez I, Lluch A, Gonzalez-Perez A, Rovira A, López-Botet M, Albanell J.

Clin Cancer Res. 2019 Mar 1;25(5):1535-1545. doi: 10.1158/1078-0432.CCR-18-2365. Epub 2018 Dec 6.

PMID:
30523021
20.

Methylation deregulation of miRNA promoters identifies miR124-2 as a survival biomarker in Breast Cancer in very young women.

Oltra SS, Peña-Chilet M, Vidal-Tomas V, Flower K, Martinez MT, Alonso E, Burgues O, Lluch A, Flanagan JM, Ribas G.

Sci Rep. 2018 Sep 26;8(1):14373. doi: 10.1038/s41598-018-32393-3.

21.

Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy.

Cruz C, Llop-Guevara A, Garber JE, Arun BK, Pérez Fidalgo JA, Lluch A, Telli ML, Fernández C, Kahatt C, Galmarini CM, Soto-Matos A, Alfaro V, Pérez de la Haza A, Domchek SM, Antolin S, Vahdat L, Tung NM, Lopez R, Arribas J, Vivancos A, Baselga J, Serra V, Balmaña J, Isakoff SJ.

J Clin Oncol. 2018 Nov 1;36(31):3134-3143. doi: 10.1200/JCO.2018.78.6558. Epub 2018 Sep 21. Erratum in: J Clin Oncol. 2018 Nov 20;36(33):3348. J Clin Oncol. 2019 Feb 1;37(4):362.

22.

Mathematical Optimization to Explore Tomorrow's Sustainable Diets: A Narrative Review.

Gazan R, Brouzes CMC, Vieux F, Maillot M, Lluch A, Darmon N.

Adv Nutr. 2018 Sep 1;9(5):602-616. doi: 10.1093/advances/nmy049.

23.

Adipose tissue TSH as a new modulator of human adipocyte mitochondrial function.

Comas F, Lluch A, Sabater M, Latorre J, Ortega F, Ricart W, López M, Fernández-Real JM, Moreno-Navarrete JM.

Int J Obes (Lond). 2019 Aug;43(8):1611-1619. doi: 10.1038/s41366-018-0203-1. Epub 2018 Sep 11.

PMID:
30206337
24.

In Reply to Belkacemi and Tsoutsou.

Zeidan YH, Habib JG, de Azambuja E, Campbell I, Andersson M, Lluch A, Di Leo A, Francis PA.

Int J Radiat Oncol Biol Phys. 2018 Oct 1;102(2):467-468. doi: 10.1016/j.ijrobp.2018.06.010. No abstract available.

PMID:
30191880
25.

Correction to: Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling.

Martín M, de la Torre-Montero JC, López-Tarruella S, Pinilla K, Casado A, Fernandez S, Jerez Y, Puente J, Palomero I, González Del Val R, Del Monte-Millan M, Massarrah T, Vila C, García-Paredes B, García-Sáenz JA, Lluch A.

Breast Cancer Res Treat. 2018 Oct;171(3):635-636. doi: 10.1007/s10549-018-4883-y.

PMID:
30009323
26.

Systematic review of the evidence for sustained efficacy of dietary interventions for reducing appetite or energy intake.

Halford JCG, Masic U, Marsaux CFM, Jones AJ, Lluch A, Marciani L, Mars M, Vinoy S, Westerterp-Plantenga M, Mela DJ.

Obes Rev. 2018 Oct;19(10):1329-1339. doi: 10.1111/obr.12712. Epub 2018 Jun 25.

PMID:
29938880
27.

Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling.

Martín M, de la Torre-Montero JC, López-Tarruella S, Pinilla K, Casado A, Fernandez S, Jerez Y, Puente J, Palomero I, González Del Val R, Del Monte-Millan M, Massarrah T, Vila C, García-Paredes B, García-Sáenz JA, Lluch A.

Breast Cancer Res Treat. 2018 Oct;171(3):627-634. doi: 10.1007/s10549-018-4855-2. Epub 2018 Jun 19. Erratum in: Breast Cancer Res Treat. 2018 Jul 16;:.

28.

Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy.

Santonja A, Sánchez-Muñoz A, Lluch A, Chica-Parrado MR, Albanell J, Chacón JI, Antolín S, Jerez JM, de la Haba J, de Luque V, Fernández-De Sousa CE, Vicioso L, Plata Y, Ramírez-Tortosa CL, Álvarez M, Llácer C, Zarcos-Pedrinaci I, Carrasco E, Caballero R, Martín M, Alba E.

Oncotarget. 2018 May 29;9(41):26406-26416. doi: 10.18632/oncotarget.25413. eCollection 2018 May 29.

29.

Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy.

Templeton AJ, Rodríguez-Lescure Á, Ruíz A, Alba E, Calvo L, Ruíz-Borrego M, Santaballa A, Rodríguez CA, Crespo C, Ramos M, Gracia-Marco JM, Lluch A, Álvarez I, Casas MI, Sánchez-Aragó M, Caballero R, Carrasco E, Amir E, Martin M, Ocaña A; GEICAM 9906 Study Investigators.

Clin Transl Oncol. 2018 Dec;20(12):1548-1556. doi: 10.1007/s12094-018-1885-5. Epub 2018 May 15.

PMID:
29766456
30.

Breast cancer in pregnant patients: A review of the literature.

Martínez MT, Bermejo B, Hernando C, Gambardella V, Cejalvo JM, Lluch A.

Eur J Obstet Gynecol Reprod Biol. 2018 Nov;230:222-227. doi: 10.1016/j.ejogrb.2018.04.029. Epub 2018 Apr 23. Review.

PMID:
29728277
31.

Publisher Correction: MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer.

Gawrzak S, Rinaldi L, Gregorio S, Arenas EJ, Salvador F, Urosevic J, Figueras-Puig C, Rojo F, Del Barco Barrantes I, Cejalvo JM, Palafox M, Guiu M, Berenguer-Llergo A, Symeonidi A, Bellmunt A, Kalafatovic D, Arnal-Estapé A, Fernández E, Müllauer B, Groeneveld R, Slobodnyuk K, Stephan-Otto Attolini C, Saura C, Arribas J, Cortes J, Rovira A, Muñoz M, Lluch A, Serra V, Albanell J, Prat A, Nebreda AR, Benitah SA, Gomis RR.

Nat Cell Biol. 2018 Aug;20(8):990. doi: 10.1038/s41556-018-0052-0.

PMID:
29674681
32.

A clear trade-off exists between the theoretical efficiency and acceptability of dietary changes that improve nutrient adequacy during early pregnancy in French women: Combined data from simulated changes modeling and online assessment survey.

Bianchi CM, Huneau JF, Barbillon P, Lluch A, Egnell M, Fouillet H, Verger EO, Mariotti F.

PLoS One. 2018 Apr 11;13(4):e0194764. doi: 10.1371/journal.pone.0194764. eCollection 2018.

33.

ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors.

Guerrero-Zotano AL, Stricker TP, Formisano L, Hutchinson KE, Stover DG, Lee KM, Schwarz LJ, Giltnane JM, Estrada MV, Jansen VM, Servetto A, Gavilá J, Perez-Fidalgo JA, Lluch A, Llombart-Cussac A, Bayar MA, Michiels S, André F, Arnedos M, Guillem V, Ruiz-Simon A, Arteaga CL.

Clin Cancer Res. 2018 Jun 1;24(11):2517-2529. doi: 10.1158/1078-0432.CCR-17-2904. Epub 2018 Mar 26. Erratum in: Clin Cancer Res. 2019 Feb 15;25(4):1431.

34.

Outcomes of single versus double hormone receptor-positive breast cancer. A GEICAM/9906 sub-study.

Ethier JL, Ocaña A, Rodríguez Lescure A, Ruíz A, Alba E, Calvo L, Ruíz-Borrego M, Santaballa A, Rodríguez CA, Crespo C, Ramos M, Gracia Marco J, Lluch A, Álvarez I, Casas M, Sánchez-Aragó M, Carrasco E, Caballero R, Amir E, Martin M.

Eur J Cancer. 2018 May;94:199-205. doi: 10.1016/j.ejca.2018.02.018. Epub 2018 Mar 21.

PMID:
29573665
35.

Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial.

Zeidan YH, Habib JG, Ameye L, Paesmans M, de Azambuja E, Gelber RD, Campbell I, Nordenskjöld B, Gutiérez J, Anderson M, Lluch A, Gnant M, Goldhirsch A, Di Leo A, Joseph DJ, Crown J, Piccart-Gebhart M, Francis PA.

Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):316-324. doi: 10.1016/j.ijrobp.2018.01.105. Epub 2018 Feb 6.

PMID:
29534902
36.

MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer.

Gawrzak S, Rinaldi L, Gregorio S, Arenas EJ, Salvador F, Urosevic J, Figueras-Puig C, Rojo F, Del Barco Barrantes I, Cejalvo JM, Palafox M, Guiu M, Berenguer-Llergo A, Symeonidi A, Bellmunt A, Kalafatovic D, Arnal-Estapé A, Fernández E, Müllauer B, Groeneveld R, Slobodnyuk K, Stephan-Otto Attolini C, Saura C, Arribas J, Cortes J, Rovira A, Muñoz M, Lluch A, Serra V, Albanell J, Prat A, Nebreda AR, Benitah SA, Gomis RR.

Nat Cell Biol. 2018 Feb;20(2):211-221. doi: 10.1038/s41556-017-0021-z. Epub 2018 Jan 22. Erratum in: Nat Cell Biol. 2018 Apr 19;:.

PMID:
29358704
37.

Volar Plate Fixation to Treat Scaphoid Nonunion: A Case Series With Minimum 3 Years of Follow-Up.

Esteban-Feliu I, Barrera-Ochoa S, Vidal-Tarrason N, Mir-Simon B, Lluch A, Mir-Bullo X.

J Hand Surg Am. 2018 Jun;43(6):569.e1-569.e8. doi: 10.1016/j.jhsa.2017.12.004. Epub 2018 Jan 19.

PMID:
29358010
38.

Free Neurovascular Latissimus Dorsi Muscle Transplantation for Reconstruction of Hip Abductors.

Barrera-Ochoa S, Collado-Delfa JM, Sallent A, Lluch A, Velez R.

Plast Reconstr Surg Glob Open. 2017 Sep 26;5(9):e1498. doi: 10.1097/GOX.0000000000001498. eCollection 2017 Sep.

39.

MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation.

Lee KM, Giltnane JM, Balko JM, Schwarz LJ, Guerrero-Zotano AL, Hutchinson KE, Nixon MJ, Estrada MV, Sánchez V, Sanders ME, Lee T, Gómez H, Lluch A, Pérez-Fidalgo JA, Wolf MM, Andrejeva G, Rathmell JC, Fesik SW, Arteaga CL.

Cell Metab. 2017 Oct 3;26(4):633-647.e7. doi: 10.1016/j.cmet.2017.09.009.

40.

Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer.

Sabbaghi M, Gil-Gómez G, Guardia C, Servitja S, Arpí O, García-Alonso S, Menendez S, Arumi-Uria M, Serrano L, Salido M, Muntasell A, Martínez-García M, Zazo S, Chamizo C, González-Alonso P, Madoz-Gúrpide J, Eroles P, Arribas J, Tusquets I, Lluch A, Pandiella A, Rojo F, Rovira A, Albanell J.

Clin Cancer Res. 2017 Nov 15;23(22):7006-7019. doi: 10.1158/1078-0432.CCR-17-0696. Epub 2017 Aug 18.

41.

Critically short telomeres and toxicity of chemotherapy in early breast cancer.

Quintela-Fandino M, Soberon N, Lluch A, Manso L, Calvo I, Cortes J, Moreno-Antón F, Gil-Gil M, Martinez-Jánez N, Gonzalez-Martin A, Adrover E, de Andres R, Viñas G, Llombart-Cussac A, Alba E, Mouron S, Guerra J, Bermejo B, Zamora E, García-Saenz JA, Simon SP, Carrasco E, Escudero MJ, Campo R, Colomer R, Blasco MA.

Oncotarget. 2017 Mar 28;8(13):21472-21482. doi: 10.18632/oncotarget.15592.

42.

Dietary changes needed to reach nutritional adequacy without increasing diet cost according to income: An analysis among French adults.

Maillot M, Vieux F, Delaere F, Lluch A, Darmon N.

PLoS One. 2017 Mar 30;12(3):e0174679. doi: 10.1371/journal.pone.0174679. eCollection 2017.

43.

Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.

Cejalvo JM, Martínez de Dueñas E, Galván P, García-Recio S, Burgués Gasión O, Paré L, Antolín S, Martinello R, Blancas I, Adamo B, Guerrero-Zotano Á, Muñoz M, Nucíforo P, Vidal M, Pérez RM, Chacón López-Muniz JI, Caballero R, Peg V, Carrasco E, Rojo F, Perou CM, Cortés J, Adamo V, Albanell J, Gomis RR, Lluch A, Prat A.

Cancer Res. 2017 May 1;77(9):2213-2221. doi: 10.1158/0008-5472.CAN-16-2717. Epub 2017 Mar 1.

44.

Individual Diet Modeling Shows How to Balance the Diet of French Adults with or without Excessive Free Sugar Intakes.

Lluch A, Maillot M, Gazan R, Vieux F, Delaere F, Vaudaine S, Darmon N.

Nutrients. 2017 Feb 20;9(2). pii: E162. doi: 10.3390/nu9020162.

45.

The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene.

Tormo E, Adam-Artigues A, Ballester S, Pineda B, Zazo S, González-Alonso P, Albanell J, Rovira A, Rojo F, Lluch A, Eroles P.

Sci Rep. 2017 Jan 25;7:41309. doi: 10.1038/srep41309.

46.

CIP2A confirms its prognostic value in triple-negative breast cancer.

Cristóbal I, Zazo S, Torrejón B, Pedregal M, Madoz-Gúrpide J, Lluch A, Eroles P, Rovira A, Albanell J, García-Foncillas J, Rojo F.

Oncogene. 2017 Jun 8;36(23):3357-3358. doi: 10.1038/onc.2016.474. Epub 2017 Jan 9. No abstract available.

PMID:
28068327
47.

Physical activity and breast cancer risk by pathological subtype.

Lope V, Martín M, Castelló A, Casla S, Ruiz A, Baena-Cañada JM, Casas AM, Calvo L, Bermejo B, Muñoz M, Ramos M, de Juan-Ferré A, Jara C, Antón A, Jimeno MÁ, Lluch A, Antolín S, García-Sáenz JÁ, Estévez P, Arriola-Arellano E, Gavilá J, Pérez-Gómez B, Carrasco E, Pollán M; GEICAM, the Spanish Breast Cancer Group.

Gynecol Oncol. 2017 Mar;144(3):577-585. doi: 10.1016/j.ygyno.2016.12.014. Epub 2017 Jan 3.

PMID:
28057355
48.

Re: Nakamura T. Commentary on Histological assessment of the triangular fibrocartilage complex. J Hand Surg Eur. 2016, 41: 534-5.

Semisch M, Hagert E, Garcia-Elias M, Lluch A, Rein S.

J Hand Surg Eur Vol. 2017 Jan;42(1):101-103. doi: 10.1177/1753193416672353. No abstract available.

PMID:
30178706
49.

Recent Insights into the Development of Preclinical Trastuzumab- Resistant HER2+ Breast Cancer Models.

Gonzalez-Alonso P, Cristobal I, Zazo S, Martin-Aparicio E, Chamizo C, Madoz-Gurpide J, Rovira A, Eroles P, Lluch A, Albanell J, Rojo F.

Curr Med Chem. 2018;25(17):1976-1998. doi: 10.2174/0929867323666161216144659. Review.

PMID:
27993109
50.

Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines.

Zazo S, González-Alonso P, Martín-Aparicio E, Chamizo C, Cristóbal I, Arpí O, Rovira A, Albanell J, Eroles P, Lluch A, Madoz-Gúrpide J, Rojo F.

Am J Cancer Res. 2016 Nov 1;6(11):2661-2678. eCollection 2016.

Supplemental Content

Support Center